Day 1 - March 30, 2021 (All times PDT)
Welcome - Chad Robins, CEO & Co-founder of Adaptive Biotechnologies, 2021 LSINW Program Chair
There's No Going Back
Discover how changes accelerated by the pandemic in telehealth and remote patient monitoring are transforming care delivery and impacting drug development.
New Treatments and Potential Cures in Alzheimer’s Disease and Neurodegeneration: The Future is Here!
This panel will discuss the rapidly evolving scientific landscape in neurodegeneration, historically a very challenging space. Are there valid reasons to be optimistic in the near-to-mid-term? The panel will cover a number of hot topics, including the wide array of approaches under examination in Alzheimer’s; the utility of biomarkers in CNS; and the impact of genetics on CNS drug development, patient enrichment strategies and the discovery of new targets.
Company Presentations - Afternoon Session
The Power of Next Gen Cell Therapies: Pipedreams or Reality?
Cellular therapies have made a major impact in hematologic malignancy. This session will examine how we can extend and expand the use of cellular based immunotherapies for a greater diversity of cancers and in a greater diversity of clinical settings. Innovation in engineering cutting edge products will also be discussed.
Fast Pitch Showdown
Move over Shark Tank! Twelve life science early-stage companies compete for a $5,000 judges-pick prize and a $1,000 audience-pick prize. Judges David Kereiakes from Providence Ventures, Loretta Little from WA Research Fund, Alice Chen from Accelerator Life Science Partners, and Scott Maloney from Washington State University will decide which 60 second pitch drives the best business opportunity. Past winners include current rising stars Tasso, A-Alpha Bio, and Nanodropper.
Day 2 - March 31, 2021 (All times PDT)
Welcome - Leslie Alexandre, DrPH, President & CEO, Life Science Washington
Machine Learning: A New Approach to Drug Discovery
Modern medicine can now treat some of the most burdensome diseases. At the same time, developing new therapeutics is becoming increasingly harder, because the drug development process involves multiple long and complex steps that often ultimately fail. insitro is working to combine high-throughput data production with machine learning (ML) models to help predict the outcome of these experiments. The goal is to develop a new approach to drug development that uses high-quality data and ML models to design transformative therapies that help more people, faster, and at a lower cost.
Paying for Innovation
The time is right for a lively conversation about the kinds of drug pricing reforms our industry can support, that expand incentives for innovation without causing the financial burdens for patients and families we see too much of today.
Strategic Sandpits: What Innovations Are Driving Corporate Interest in BioPharma?
This panel will discuss how strategic investors plan to balance innovative biology with advanced data and digital technologies as they build out their portfolios.
Where Are We Now on COVID-19?
The COVID-19 pandemic has revealed the political, economic, and social gaps in our society in a way that many in the US haven’t encountered before. Diagnostic testing has emerged as one of the more significant infrastructure gaps: from COVID test development, distribution, and payment, through to public surveillance to monitor the ongoing viral spread and its mutations. This panel will touch on various aspects of COVID-19 testing while considering a looming existential question: will we be ready for the next pandemic?